METASTATIC BREAST CANCER

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This phase 3 trial tests whether adding the targeted drug inavolisib to standard maintenance therapy (Phesgo) can delay cancer growth in people with a specific genetic mutation (PIK3CA) in HER2-positive advanced breast cancer. About 230 participants who have already completed ini…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 40 adults with advanced breast cancer that has no HER2 protein (HER2-0). Participants get the drug every 3 weeks. The goal is to see if it shrinks tumors and which patients benefit most.

This study follows over 1,100 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. Researchers will compare how long patients stay on trastuzumab deruxtecan (a targeted drug) versus standard chemotherapy before needing a new treatment. The goal is t…

This early-stage study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, lung, or colorectal cancer) that have not responded to standard treatments. The drug is designed to block two cancer-driving proteins (PI3K and RAS). Researchers will check safe…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with various types of breast cancer (…

This early-phase trial is testing a new drug called BGB-21447, which blocks a protein that helps cancer cells survive. It is given together with standard hormone therapy (fulvestrant) and sometimes another targeted drug (BGB-43395). The study involves 120 adults with HR+/HER2- me…

This study tests whether a new drug combination (lasofoxifene plus abemaciclib) works better than a standard combination (fulvestrant plus abemaciclib) for people with advanced ER+/HER2- breast cancer that has a specific gene change (ESR1 mutation). About 500 adults whose cancer …

This study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-) that has returned or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adults a…

This study is testing many different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. Researchers are looking at which combinations work best for different cancer types, such as triple-negative or hormone receptor-positive…

This study tests whether adding two immunotherapy drugs (CDX-1140 and CDX-301) to standard chemotherapy (PLD) is safe and helps control metastatic HER2-negative breast cancer. About 30 people with advanced cancer that has not responded to other treatments will take part. The goal…

This phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has a PIK3CA gene change and has stopped responding to hormone therapy. About 500 participants in China will receive inavolisib as part of their regular care. Rese…

This study tests a new treatment for people with metastatic breast or prostate cancer that has stopped responding to standard therapies. Participants receive infusions of their own immune cells that have been armed with a special antibody to help them find and attack cancer cells…

This study compares a combination of two drugs (elacestrant and capecitabine) to capecitabine alone in people with advanced estrogen receptor-positive breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to one of the two t…

This phase 3 trial is testing trastuzumab deruxtecan (T-DXd), a drug that delivers chemotherapy directly to cancer cells with a specific marker (HER2). It includes 250 people with advanced breast cancer that has low or even no HER2, which is often harder to treat. Participants re…

This study tests a combination of two drugs—elacestrant and trastuzumab deruxtecan—in people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultralow) that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The goal is to find the s…

This study compares two drug combinations for people with a type of advanced breast cancer (HR+/HER2-) that has a specific genetic change (PIK3CA mutation) and has worsened after prior treatment. About 540 adults will receive either the experimental drug RLY-2608 plus fulvestrant…

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, pro…

This phase 2 trial is testing a combination of three drugs—alpelisib, L-NMMA, and nab-paclitaxel—in people with a rare, aggressive form of breast cancer called metaplastic breast cancer (MpBC) that has spread or is locally advanced. The study aims to find the best dose and see if…

This phase 2 trial tests whether delivering high-dose chemotherapy directly to the liver (using a special system) followed by standard cancer drugs works better than standard drugs alone for people with breast cancer that has spread mainly to the liver. About 90 participants will…

This study tests a high dose of the chemotherapy drug methotrexate given through a vein in people with breast cancer that has spread to the lining of the brain. The goal is to see if it helps them live longer. The trial includes adults with triple-negative, HER2-positive, or horm…

This early-phase study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard therapies. The main goals are to check the drug's safety and find the right dose, while also seeing if …

This early-stage trial tests the safety of a new drug called ERX-315 in 36 adults with advanced solid tumors (like breast, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. Participants receive the drug intravenously twice a week at increasing do…

This early-stage trial tests the drug abemaciclib (a CDK4/6 inhibitor) given together with targeted radiation for people with metastatic HR+ HER2- breast cancer that has spread to bone. The main goal is to find the safest dose of abemaciclib when combined with radiation. About 28…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This early-phase trial is testing a new type of cell therapy called p95HER2.CAR-TECH2Me for people with advanced HER2-positive breast, gastric, or endometrial cancers that have spread. The treatment uses a patient's own immune cells, which are modified in a lab to better recogniz…

This early-phase trial tests whether freezing a tumor (cryoablation) can boost the immune response to the drug pembrolizumab in people with metastatic or locally advanced triple negative breast cancer. About 30 participants will be randomly assigned to receive either the combinat…

This study tests whether adding surgery and targeted radiation to standard treatment helps people with HER2-positive breast cancer that has spread to up to 5 spots in the body. About 178 adults will be randomly assigned to receive either standard care alone or standard care plus …

This study tests if a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) is safe and works for people with ER-positive, HER2-negative breast cancer that has spread. About 54 adults whose cancer has not responded to other treatments will take part. The goal is…

This phase 2 trial tests whether giving the chemotherapy drug capecitabine in a flexible, response-based way (adaptive therapy) can better control metastatic ER-positive breast cancer. About 35 adults with advanced, hormone-resistant disease will receive doses that are adjusted b…

This study tests whether adding tocilizumab, an anti-inflammatory drug, to standard chemotherapy improves outcomes for people with metastatic triple-negative or ER-low breast cancer. Researchers will compare the combination to chemotherapy alone in 168 Black and non-Black patient…

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy for people with a common type of advanced breast cancer (HR+/HER2-) that has stopped responding to hormone therapy. About 430 participants will be randomly assigned to receive either SKB264 or one of …

This early-stage study is testing a new oral drug, PF-08032562, in people with advanced breast or colorectal cancer that has spread. The drug is given alone or with other cancer treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. Abo…

This phase 3 trial tests a new drug called SKB264 against standard chemotherapy in 376 people with advanced HR+/HER2- breast cancer that has worsened after at least one chemotherapy. The goal is to see if SKB264 can slow cancer growth or improve survival. Participants are randoml…

This phase 2 study tests estradiol, a form of estrogen, in postmenopausal women with advanced ER+ breast cancer that has stopped responding to other hormone therapies. The goal is to see if patients with a specific genetic change (ESR1 mutation) benefit more than those without it…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…

This study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the triple combination is safe and can reduce high blood sugar side effects often caused by the standard drugs. About 52 adul…

This study tests whether giving a precise, high-dose radiation treatment called SBRT to one growing tumor can help people with metastatic breast cancer keep their disease under control. Participants continue their usual drug therapy while receiving SBRT to a single site where can…

This early-stage study tests a new oral drug, BBI-940, in people with advanced or metastatic breast cancer that has not responded to standard treatments. The drug works by breaking down a protein that helps cancer cells grow. The study aims to find the safest dose and check for s…

This phase II trial is testing whether an anti-viral drug called valganciclovir (Valcyte) can help treat breast cancer that has spread to the brain. The study includes 28 adults with progressive brain metastases who also have evidence of a common virus called CMV. Participants ta…

This study tests whether giving a different antibody-drug conjugate (ADC) to people with advanced breast cancer who have already tried an ADC can still shrink tumors or slow the disease. About 160 participants will receive one of several ADCs or a targeted pill. The goal is to se…

This early-stage study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants will take pa…

This study tests whether a new treatment called Bria-IMT, given with an immunotherapy drug, helps people with advanced metastatic breast cancer live longer compared to standard chemotherapy. About 404 adults whose cancer has not responded to other treatments will participate. The…

This study tests an experimental drug called SHR-A1811 in people with advanced breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. The trial enrolls 150 adults with HER2-positive or HER2-low breast cancer who have not had radiation …

This study is for people with metastatic breast cancer that has spread to the brain, with at least two brain tumors. Participants receive an immunotherapy drug called pembrolizumab every three weeks, plus a precise, one-time radiation treatment to just one of the brain tumors. Th…

This early-phase trial is testing a new way to give the cancer drug T-DXd (Enhertu) — as a shot under the skin instead of an IV drip. The study will enroll 76 adults with metastatic solid tumors to find the safest dose and see how well the body handles it. Researchers will also c…

This study tests a new drug called OP-1250 (palazestrant) against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can slow cancer growth better than standard care. The…

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with a common type of advanced breast cancer (hormone receptor positive, HER2-negative). About 20 participants whose cancer has spread or retur…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This study tests whether giving a very focused, high-dose radiation treatment (SBRT) to all visible cancer spots can delay the cancer from getting worse in people with breast or lung cancer that has spread to 1-5 places. About 145 participants will either receive standard care al…

This study is for people with advanced breast cancer that is androgen receptor-positive (AR+) and either triple-negative or low in estrogen receptors. It tests whether the drug enzalutamide, alone or combined with mifepristone, can control the cancer as well as standard chemother…

This study tests a combination of two drugs, tucatinib and trastuzumab, in people with a specific type of advanced breast cancer that has a mutation in the HER3 gene. The cancer must be HER2-negative and has already been treated with at least two prior chemotherapies. The goal is…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive/HER2-negative breast cancer. About 34 adul…

This study is for people with breast cancer that has spread to only a few spots in the body (oligometastasis). It tests whether adding focused treatments like radiation or surgery to the cancer spots, along with standard drug therapy, can help people live longer. About 340 partic…

This study tests a new drug called FWD1802 in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find a safe dose and see if it can shrink tumors. About 99 women with cancer that has spread or cannot be removed by surgery will take part. The study has…

This study tests whether precisely targeted radiation (SBRT) can treat a few growing cancer spots in patients with metastatic breast cancer, allowing them to stay on their current systemic therapy instead of switching to a new drug. Researchers will also look at whether circulati…

This study tests a new approach for metastatic breast cancer patients. Doctors take a biopsy of a tumor and grow it in the lab to create a 'tumorogram'—a map showing which drugs might work best. Then, patients receive a treatment chosen based on this map. The goal is to see if th…

This study tests a new drug called HRS-8080 against standard treatments chosen by doctors for women with advanced breast cancer that has worsened after hormone therapy. About 240 women aged 18-75 will take part. The main goal is to see if HRS-8080 can delay cancer growth longer t…

This study tests an experimental oral drug called PMD-026 in people with metastatic breast cancer that has spread and is no longer curable. The drug targets a protein called RSK2 found in some tumors. The trial will check safety and how well the drug works alone or with another h…

This phase 2 trial is testing whether using gene tests (MammoPrint and BluePrint) to guide treatment can help people with a certain type of advanced breast cancer (HR+, HER2-negative) live longer. 64 participants will receive either chemotherapy (capecitabine) or hormone therapy …

This study tests a lower daily dose of the chemotherapy drug capecitabine in 40 patients aged 60 or older, or those who are frail, with advanced breast cancer. The goal is to see if this gentler dose can still shrink tumors while causing fewer side effects. Participants will take…

This study is for people with a common type of advanced breast cancer (ER-positive/HER2-negative) that cannot be removed by surgery or has spread. It tests a new drug called FWD1802 combined with other treatments to find the safest dose and see if it shrinks tumors. About 196 par…

This Phase 2 trial is testing whether the drug sacituzumab govitecan (Trodelvy) can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2 low or ultra low) who have already received another targeted drug called T-DXd. The study will enroll 75 participan…

This Phase 2 trial tests a drug called patritumab deruxtecan in people with advanced hormone-receptor-positive breast cancer that has stopped responding to hormone therapy and chemotherapy. The drug is designed to seek out and destroy cancer cells that have a protein called HER3 …

This study tests whether a blood test measuring thymidine kinase activity (TKa) can help doctors decide early if a patient's breast cancer treatment is working. Patients with HR+ HER2- metastatic breast cancer start standard therapy with a CDK4/6 inhibitor and endocrine therapy. …

This study tests a drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). The cancer has continued to grow despite at least two prior hormone treatments. The goal is to find the best dose of alisertib and see if t…

This pilot study tests a new way of giving several already-approved chemotherapy drugs in a specific order to treat hormone-positive metastatic breast cancer. The idea is to hit the cancer with a 'first strike' and then a 'second strike' to make treatment more effective. The stud…

This early-stage study tests the safety of combining two drugs, olaparib and estradiol, in post-menopausal women with advanced ER+/HER2- breast cancer that has spread or returned. The goal is to find the best dose for future studies. About 6 participants will be enrolled.

This phase 2 trial is testing two antibody-drug conjugates—trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan (Dato-DXd)—in people with HER2-negative metastatic breast cancer whose disease has worsened after prior antibody-drug conjugate therapy. Participants will receiv…

This early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…

This phase 2 trial is testing whether adding a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) to elacestrant works better than elacestrant alone for people with advanced ER+/HER2- breast cancer that has already been treated with a CDK4/6 inhibitor. The study will enro…

This early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have not responded to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The study will first find a safe dose, then test i…

This early-stage trial is testing a new drug called [177Lu]Lu-ABY-271, which delivers a small dose of radiation directly to HER2-positive breast cancer cells. The study will enroll 21 people with advanced or metastatic HER2-positive breast cancer to see if the drug is safe, toler…

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells or donor cells. The cells are modified and killed in the lab, then injected under the skin to train the immune system to attack the cancer. The study includes 50 adults with metastatic melan…

This early-stage study is testing a new drug called RLY-2608, which is designed to block a specific mutant protein (PIK3CA) that helps some cancers grow. The trial includes people with advanced solid tumors or breast cancer that has not responded to other treatments. Participants…

This study is testing a new device that uses specially designed bacteria and laser technology to find and study rare tumor cells in the blood of breast cancer patients. The goal is to improve early detection and personalized treatment. The study will include 80 women with either …

This study tests a new imaging approach for people with advanced breast or prostate cancer. It uses two radioactive tracers to find tumors that have a specific protein (GRPR). The goal is to see if this method is safe and can help doctors see where the cancer is in the body. Abou…

This study tests a new type of PET/CT scan that uses a radioactive tracer called 68Ga-ABS011 to detect HER2, a protein found on some cancer cells. The goal is to see if this scan can more accurately determine HER2 status in people with metastatic breast cancer or other solid tumo…

This study is testing whether routine brain MRIs can find brain metastases in stage IV breast cancer patients who have no neurological symptoms. Researchers will scan 170 participants at the start and again at 6 months or when their cancer first progresses. The goal is to see how…

This study enrolls 100 people with metastatic, hormone receptor-positive, HER2-negative breast cancer to compare different genetic testing methods for detecting PIK3CA mutations. Researchers will check how well newer DNA sequencing techniques match up with standard PCR tests. The…

This study is testing whether regular MRI scans of the brain can find cancer that has spread from the breast to the brain, even before symptoms appear. It involves 214 people with metastatic or inflammatory breast cancer. The goal is to see if early detection through screening im…

This study compares two types of PET scans to see which is better at finding and tracking metastatic lobular breast cancer. About 30 adults with this type of cancer will receive both an experimental FES PET/CT scan and a standard FDG PET/CT scan. The goal is to improve detection …

This pilot study is testing a new type of PET scan that uses a tracer called [68Ga]Ga-PentixaFor to see if it can detect metastatic triple-negative breast cancer as well as or better than the standard FDG PET scan. The study will enroll 12 patients with metastatic triple-negative…

This study is testing a new, highly sensitive blood test to measure tiny particles called extracellular vesicles that are released by breast cancer cells. Researchers will compare levels in women with early or metastatic breast cancer to healthy controls. The goal is to see if th…

This study tests a special PET scan that uses a radioactive tracer to detect HER2 protein on cancer cells. The goal is to see if this scan can better identify which patients with metastatic breast cancer will benefit from a targeted drug called T-DXd. About 70 women with advanced…

This study tests whether a special cooling cap can reduce hair loss in people with metastatic breast cancer who are receiving certain chemotherapy drugs. About 120 participants will either use the Paxman Scalp Cooling System or not, and researchers will compare hair loss rates an…

This study tests a remote coaching program called PRISM for people recently diagnosed with metastatic breast cancer. The program teaches stress management, goal setting, and coping skills through video sessions. Researchers want to see if it improves resilience and quality of lif…

This study tests whether a 16-week virtual exercise program can improve fitness, muscle strength, and quality of life in people with indolent (slow-growing) metastatic breast cancer. Participants work with a trainer three times a week via video calls. The goal is to see if exerci…

This study tests whether a remotely delivered program that combines mindfulness, physical activity tracking, and social support is acceptable and feasible for people with metastatic breast cancer. The program lasts 8-12 weeks and includes a wearable activity tracker and weekly ch…

This study tests two supportive care programs—meditation and discussion sessions—for people with advanced (stage IV) cancer and their family caregivers. Researchers want to see if these programs can reduce depressive symptoms and improve quality of life. About 400 patient-caregiv…

This study tests whether a 12-week home exercise program (aerobic and resistance training) can reduce fatigue in 80 people with metastatic breast cancer who are taking Enhertu. Participants exercise on their own, and researchers will measure changes in fatigue and how well people…

This study looks at whether a 16-week exercise program called Get Real and Heel can increase physical activity and improve well-being in people with metastatic breast cancer. Researchers will enroll 50 participants to see if the program is feasible and helps with symptoms, qualit…

This study tests a five-session palliative care program called TARGET-PC for people with metastatic breast cancer and their caregivers. The goal is to help patients talk with their doctors about their goals and values for care, and to have those preferences documented. The study …

This pilot study tests a program called ACCESS, where a community navigator helps Black and Latina women with metastatic breast cancer connect to supportive care and community resources. Participants receive six coaching sessions and monthly check-ins over 16 weeks. The goal is t…

This study explores whether regular video or phone check-ins between hospice patients with advanced breast cancer and their oncology team can improve the hospice experience. About 200 participants, along with their caregivers and nurses, will take part. The goal is to see if this…

This study is collecting blood samples from 170 people with metastatic breast cancer to look for ESR1 gene mutations, which can make cancer resistant to hormone therapy. Researchers will compare these blood-based results with standard tissue tests. The goal is to better understan…

This study looks at whether starting with a lower dose of CDK4/6 inhibitor pills (palbociclib or ribociclib) and gradually increasing the dose helps older adults (age 65+) with metastatic breast cancer tolerate side effects better and stay on treatment longer. About 500 participa…

This study is testing whether a special PET/CT scan that looks for a protein called PSMA can help predict resistance to anti-androgen therapy in people with a specific type of metastatic breast cancer (HER2-negative, AR-positive). About 13 participants will receive an injection o…

This study collects tumor tissue and blood samples from 10,000 women with breast cancer to build a large biorepository. Researchers will analyze these samples to find molecular markers that may predict how well a patient responds to therapy. The goal is to better understand breas…

This study looks at whether emotional distress (like anxiety or depression) affects how well first-line therapy works in people with metastatic breast cancer. Researchers will follow 1000 patients starting standard treatments based on their cancer type. The goal is to see if thos…

This study is observing about 800 adults with advanced breast cancer (HER2-positive, low, or ultralow) who are receiving the drug trastuzumab deruxtecan as part of their normal care in Germany. Researchers are tracking how long patients stay on the drug before switching treatment…

This study is looking at whether a blood test called DiviTum TKa can predict when hormone-receptor-positive, HER2-negative metastatic breast cancer stops responding to treatment. About 100 participants will give blood samples before and during their standard therapy. The goal is …

This study compares three different blood tests (CellSearch, Parsortix, and SmartCatch) to see which one best detects circulating tumor cells in patients with metastatic breast or prostate cancer. Researchers will take blood samples from 54 patients before they start a new treatm…

This pilot study is testing whether taking endocrine therapy in the morning or evening makes a difference for people with metastatic breast or prostate cancer. Fifty participants will be randomly assigned to take their medication either within an hour of waking or within an hour …

This study gathers information from over 42,000 people with metastatic breast cancer treated at 18 French cancer centers since 2008. Researchers will look at how treatments have changed over time and how they affect survival. The goal is to learn from real-world data to improve f…

This observational study tracks 800 people with metastatic breast cancer to see if differences in HER2 levels across tumors affect how well trastuzumab deruxtecan works. Researchers will compare progression-free and overall survival based on HER2 patterns. The goal is to better u…

This study is for people with metastatic breast cancer, including estrogen receptor-positive and triple-negative types. It uses biomarkers from tumors and blood to guide treatment choices, comparing how long the cancer stays controlled on the new therapy versus the previous one. …

This study explores whether certain gene variants (UGT1A1) increase the risk of severe side effects from powerful breast cancer drugs called antibody-drug conjugates. Researchers will enroll 70 adults with advanced breast cancer who are starting treatment with sacituzumab-govitec…

This study is testing a device called ScreenCell that counts circulating tumor cells (CTCs) in a blood sample from breast cancer patients. Researchers want to see if changes in CTC numbers over time can help track how the cancer is progressing. The study will include 93 women wit…

This study is a registry that collects information from 1867 people with advanced breast cancer that cannot be removed by surgery or has spread. Researchers will track different breast cancer subtypes and patient characteristics to better understand the disease in real-world sett…

This study is tracking 1,500 Swedish patients with metastatic breast cancer who are taking palbociclib as part of their treatment. Researchers want to see how long patients stay on the drug, what their characteristics are, and how they fare over time. It's an observational study,…

This study is creating a registry for people with a rare type of breast cancer called invasive lobular carcinoma that has spread. Researchers will collect data from about 12 participants to develop a new tool that better measures how well treatments are working. The goal is to im…

This study is testing whether a blood test that looks for cancer cells and genetic material can help doctors decide on treatments for metastatic breast cancer. About 187 adults with advanced breast cancer will participate. The goal is to see if the test results change how doctors…

This study looks at whether it is possible to take multiple tissue samples (biopsies) from different tumor sites in people with metastatic breast cancer at different times during treatment. The goal is to learn how cancers change and become resistant to therapy. About 200 adults …

This study compares two types of scans—FDG-PET/CT and standard CT—to see which one better tracks breast cancer that has spread. Researchers want to know if the newer scan can find cancer growth earlier, helping doctors start new treatments sooner and potentially extend patients' …

This study is collecting tumor samples from 1,050 people with early or metastatic breast cancer to analyze fat storage and organelle properties in cancer cells. Researchers aim to create a detailed atlas of these features across different breast cancer subtypes. The goal is to be…

This study looks at whether giving doctors the molecular subtype of a patient's metastatic breast cancer helps them pick more effective treatments. It involves 500 adults with metastatic breast cancer who are starting or have had one prior treatment. The main goal is to see how o…

This study tests a new device that prepares blood samples to look for cancer cells and DNA. Researchers will collect blood from 20 healthy volunteers and 25 people with advanced breast cancer. The goal is to see if the device works well for liquid biopsy, a less invasive way to d…

The CATCH trial is a large observational study for people with metastatic breast cancer. It uses advanced genetic testing on tumor biopsies to find unique biomarkers and drug targets. The goal is to create a precision medicine platform that helps guide patients toward the most pr…

This study is testing whether certain substances in the blood can help predict where breast cancer might spread. Researchers will measure levels of a protein called PTEN and specific microRNAs in blood samples from 160 women: 80 with metastatic breast cancer, 40 with early-stage …

This study is for people with advanced breast cancer who are about to start treatment with the drug T-DXd. The goal is to find markers in the blood that could predict serious side effects, like lung inflammation. By collecting blood samples before and during treatment, researcher…

This pilot study tests whether a special PET scan (FES-PET/CT) can help doctors find the best dose of tamoxifen for people with metastatic breast cancer that has an ESR1 mutation. These mutations can make standard tamoxifen doses less effective. The study will enroll 12 participa…

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their routine care. Researchers will collect blood samples and medical records to see how long the cancer stays controlled with each ADC treatmen…

This study is looking at proteins and genes in breast cancer tumors from 1,780 patients. Researchers want to understand how breast cancer progresses and why it sometimes comes back. By comparing primary and recurrent tumors, they hope to find markers that could predict disease ou…

This study will look at medical records of 60 Russian patients with advanced HER2-positive breast cancer who have received trastuzumab deruxtecan. Researchers want to see how long the drug keeps cancer from growing and how safe it is. The goal is to understand how well this treat…

This study asks 15 doctors, nurses, and physician assistants about a new computer tool that estimates how long patients with metastatic breast cancer might live. The goal is to see if the tool is easy to use and helpful for discussing end-of-life care. Researchers will interview …

This study is tracking 2,000 people with metastatic breast cancer to understand how the cancer changes over time and in response to treatment. Researchers will analyze tumor and blood samples to find genetic markers that predict which therapies work best. The goal is to develop b…